Cellectar Biosciences, Inc. Resources
News & Media
Investors
Contact
Cellectar Biosciences, Inc.
Home
About
Overview
Partnerships
Management Team
Board of Directors
Technology
Overview
Posters & Publications
Product Pipeline
Overview
CLR 131
Clinical Trials
Overview
For Patients with Relapsed or Refractory Multiple Myeloma
Recruiting
For Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Not yet recruiting
For Relapsed or Refractory Select B-Cell Malignancies
Recruiting
News & Media
Investors
Contact
Contact
Clinical Trials
Clinical Trials
Overview
For Patients with Relapsed or Refractory Multiple Myeloma
For Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
For Relapsed or Refractory Select B-Cell Malignancies
Contact us for more information on the CLR 131 Clinical Trials
Name
Email
I am a:
Patient
Friend, Family, Caregiver
Physician/Healthcare Provider
Clinical Trial
Select Your Trial
Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies
Message